A long-acting synthetic analog of the hormone amylin, developed for weight management and most often studied alongside semaglutide in the fixed combination known as CagriSema. It remains investigational.
Mechanism under study
Cagrilintide is an agonist at amylin and calcitonin receptors. In trials it is proposed to slow gastric emptying and promote satiety, effects thought to complement the GLP-1 pathway targeted by semaglutide.
Research-reported dosing
Investigational. Obesity trials escalated once-weekly subcutaneous doses up to roughly 2.4 mg; in the CagriSema combination it is paired 1:1 with semaglutide (2.4 mg + 2.4 mg). Not approved as a standalone product.
5 mg vial + 2 mL bacteriostatic water = 2500 mcg/mL.
A 2.4 mg dose ≈ 96 units (25 mcg per unit).
Open this mix in the calculator →Dosing figures describe how this compound appears in the research literature and research-community references. They are not a recommendation for human use.
Cagrilintide FAQ
What is Cagrilintide?
A long-acting synthetic analog of the hormone amylin, developed for weight management and most often studied alongside semaglutide in the fixed combination known as CagriSema. It remains investigational.
What is the half-life of Cagrilintide?
Long — pharmacokinetics support once-weekly subcutaneous dosing, reported on the order of about a week.
What is the research-reported dosing for Cagrilintide?
Investigational. Obesity trials escalated once-weekly subcutaneous doses up to roughly 2.4 mg; in the CagriSema combination it is paired 1:1 with semaglutide (2.4 mg + 2.4 mg). Not approved as a standalone product.
How is Cagrilintide reconstituted?
5 mg vial + 2 mL bacteriostatic water = 2500 mcg/mL.
Is Cagrilintide FDA-approved?
Cagrilintide has an approved status in at least one context — see the overview above for the specific brand, region, and indication. Research-grade material sold separately is for laboratory use only.
References
Related peptides
Semaglutide
GLP-1 receptor agonist
A long-acting GLP-1 receptor agonist, FDA-approved for type-2 diabetes and chronic weight management under brand names Ozempic, Wegovy, and Rybelsus. One of the most-studied incretin peptides.
Tirzepatide
Dual GIP / GLP-1 receptor agonist
A dual GIP and GLP-1 receptor agonist, FDA-approved as Mounjaro (type-2 diabetes) and Zepbound (weight management). Trials reported notably large reductions in body weight.
Retatrutide
Triple GIP / GLP-1 / glucagon receptor agonist
An investigational 'triple agonist' targeting the GIP, GLP-1, and glucagon receptors. Phase-2 trials reported among the largest weight reductions seen for an incretin agent. Not approved.